Glucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant
Preprint
Abstract
Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in GCKR , the gene encoding GKRP, strongly associate with fatty liver disease, hypertriglyceridemia, and hypercholesterolemia. Here, we sought to investigate the mechanisms by which a common GKRP variant affects hepatic lipid and cholesterol metabolism. Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Gck . Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Gck in mice recapitulated several effects of GKRP P446L, including increased hepatic cholesterol and triglyceride content. The elevated cholesterol was associated with increased cholesterogenic gene expression and cholesterol synthesis. Hepatic expression of an alternative hexokinase (HKII) normalized the effects of GCK-deficiency, suggesting that impaired glucose phosphorylation underlies the phenotype. Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant. Highlights: The GKRP P446L variant reduces GKRP protein abundance and diminishes GCK activity. Expression of GKRP P446L in mouse hepatocytes increases serum cholesterol levels. GCK activity suppresses cholesterogenic gene expression and cholesterol synthesis.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK125497)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK111715)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK126194)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK019525)
This publication has 40 references indexed in Scilit:
- Effects of coding variants in the glucokinase regulatory protein gene on hepatic glucose and triglyceride metabolism suggest a gene regulatory function of glucokinaseMetabolism, 2025
- The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326Molecular Metabolism, 2023
- Rapid in vivo multiplexed editing (RIME) of the adult mouse liverHepatology, 2022
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆Journal of Hepatology, 2020
- Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes riskDiabetologia, 2011
- Molecular Physiology of Mammalian GlucokinaseCellular and Molecular Life Sciences, 2008
- Structural Basis for Allosteric Regulation of the Monomeric Allosteric Enzyme Human GlucokinaseStructure, 2004
- Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinaseFEBS Letters, 1999
- The regulatory protein of liver glucokinaseAdvances in Enzyme Regulation, 1992